Biogen touts glimpses of efficacy in early study of tau-lowering drug
An experimental genetic medicine designed to short-circuit the production of the Alzheimer’s-linked protein tau showed signs of slowing cognitive decline in a small study from Biogen.
The company has previously demonstrated that the drug, an antisense oligonucleotide dubbed BIIB080, reduced levels of tau in the brain. The new results, presented Wednesday morning at the Clinical Trials on Alzheimer’s Disease conference in Boston, suggest that the 16 people who got a high dose of the drug in the 46-person study progressed more slowly than otherwise expected after two years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.